if patient is taking 30u basalog daily then how much he need awiqli insulin weekly
Reading File
Finding Sources
Searching the Web
Awiqli insulin icodec conversion from daily glargine dose calculator
Here is the complete conversion guide for switching from Basalog 30 units/day to Awiqli (insulin icodec):
Basalog 30 U/day → Awiqli Weekly Dose
Basalog = insulin glargine 100 U/mL (once-daily basal insulin). The conversion formula per the official Awiqli prescribing information is:
Formula
| Week | Formula | Calculation for 30 U/day |
|---|---|---|
| Week 1 (loading dose) | Daily dose × 7 × 1.5, rounded to nearest 10 units | 30 × 7 × 1.5 = 315 → 320 units |
| Week 2 onward (maintenance) | Daily dose × 7, rounded to nearest 10 units | 30 × 7 = 210 → 210 units |
Why a Higher Week 1 Dose?
Awiqli (insulin icodec) is a U-700 insulin that binds to albumin and builds up a circulating depot over the first week. The 1.5x loading dose in Week 1 is a one-time optional dose to quickly achieve steady-state insulin levels and avoid hyperglycemia during the transition. It should only be given if hypoglycemia risk is acceptable.
- If hypoglycemia risk is a concern (e.g., renal impairment, history of hypoglycemia): skip the loading dose and start directly at 210 units in Week 1
- If glycemic control is a priority and hypoglycemia risk is low: use the 320 units loading dose in Week 1, then 210 units from Week 2 onward
Key Practical Points
- Timing: Give the first Awiqli dose the day after the last Basalog injection
- Concentration: Awiqli is U-700 (700 units/mL) - use only the dedicated FlexTouch pen, NOT a standard insulin syringe
- Same day weekly: Administer on the same day every week
- Peak effect: Highest insulin effect occurs on Days 2-4 after injection - monitor for hypoglycemia on those days
- Titration from Week 3: Adjust dose based on fasting blood glucose trends and glycemic goals
- CGM/SMBG: Blood glucose monitoring is important, especially in the first few weeks
- Not approved for Type 1 Diabetes by the FDA currently
Summary for 30 U Basalog → Awiqli
| Dose | |
|---|---|
| Week 1 (with loading) | 320 units |
| Week 1 (without loading) | 210 units |
| Week 2+ (maintenance) | 210 units |
Always individualize based on the patient's hypoglycemia risk, renal function, and overall glycemic control.
will its price get lower or always will be 2k+ does it have any genric
Searching the Web
Awiqli insulin icodec price India 2025 2026 generic biosimilar
Searching the Web
insulin icodec patent expiry biosimilar timeline
Great info found. Here's the full picture:
Awiqli Price in India & Generic Outlook
Current Price (July 2026 launch in India)
| Pack | Price | Units |
|---|---|---|
| 1 ml FlexTouch pen | Rs 2,611 | 700 units |
| 3 ml FlexTouch pen | Rs 7,833 | 2,100 units |
| Per unit cost | Rs 3.73-3.78/unit | - |
For your patient on 210 units/week: approx Rs 261 per week (Rs ~1,044/month). That's actually cheaper per unit than most second-generation daily basal analogs currently.
Is There a Generic / Biosimilar?
No. Not now, and not anytime soon.
Here's why:
-
Awiqli is a biologic - it cannot have a "generic" in the traditional sense. The equivalent would be a biosimilar, which requires separate clinical trial data and regulatory approval.
-
Novo Nordisk just launched it - the product is brand new (FDA approved 2023, India July 2026). Patent and regulatory exclusivity protection lasts 12+ years typically for biologics.
-
Biosimilar timeline: Given the recent launch, a biosimilar version of insulin icodec is realistically 10-15 years away at minimum - possibly 2035-2038 or later. Novo Nordisk has historically filed layered patent protections on delivery devices, formulations, and manufacturing processes that extend protection even longer (median ~17.6 years of total protection for insulin products historically).
-
Indian manufacturers like Sun Pharma, Dr. Reddy's, Biocon are capable of making insulin biosimilars - but they would need to file for icodec biosimilars, complete clinical studies, and wait for patent expiry. No such program has been announced yet.
Will the Price Drop?
Possibly slightly, but not dramatically for many years. Here's a realistic breakdown:
| Timeframe | What to Expect |
|---|---|
| Now - 2028 | Fixed at launch price; Novo Nordisk controls market entirely |
| 2028-2032 | Possible modest price reductions if adoption is slow, or government negotiations |
| 2035+ | Biosimilar entry possible - prices could fall 30-60% |
| 2040+ | Multiple biosimilars = significant price competition (like what happened with glargine) |
Bottom Line for Your Patient
- At 210 units/week, the cost is roughly ~Rs 1,000-1,100/month - actually comparable to or slightly less than daily premium basal analogs
- The convenience factor (1 injection/week vs 30 injections/month) is significant
- No generic/biosimilar exists and won't for at least a decade
- If cost is a concern now, Basalog (glargine) remains the affordable option at Rs 345-453 per 70 units daily
calculate its cost in uzbekistan
Searching the Web
Awiqli insulin icodec price Uzbekistan 2025 2026
Searching the Web
USD to Uzbekistan som exchange rate 2026
Important note first: Awiqli is not officially launched in Uzbekistan yet. As of now, it has only been launched in a handful of countries (US approval March 2026, India July 2026 - 7th country globally). Uzbekistan is not among them.
However, here is the cost estimate based on available reference prices:
Awiqli Cost Estimate in Uzbekistan
Exchange Rate (August 2026)
1 USD = ~11,935 UZS (Uzbekistani Som) - current rate
Based on US Price (most relevant reference)
The US price (Canada-submitted price) is $78.05 per 1.5 ml pen (1,050 units)
| Item | USD | UZS (Som) |
|---|---|---|
| 1.5 ml pen (1,050 units) | $78.05 | ~931,500 so'm |
| 3 ml pen (2,100 units) | ~$156.10 | ~1,863,000 so'm |
| Per unit cost | ~$0.074 | ~883 so'm |
| 210 units/week (your patient) | ~$15.60 | ~186,000 so'm/week |
| Monthly cost (4 weeks) | ~$62.40 | ~744,000 so'm/month |
| Annual cost | ~$811 | ~9,680,000 so'm/year |
Based on India Price (if imported via India)
India price: Rs 2,611 per 700-unit pen = ~$27.4 USD
| Item | INR | UZS (Som) |
|---|---|---|
| 700-unit pen | Rs 2,611 | ~328,000 so'm |
| 210 units/week | ~Rs 783 | ~98,400 so'm/week |
| Monthly cost | ~Rs 3,132 | ~393,600 so'm/month |
Context: Is This Affordable in Uzbekistan?
Average monthly salary in Uzbekistan is roughly 3,000,000-4,000,000 so'm (~$250-335/month). At US pricing, Awiqli would cost ~744,000 som/month - that's roughly 20-25% of an average monthly salary, which is very expensive.
At India's pricing (if available through import), it would be ~393,600 som/month (~10-13% of average salary) - still significant but more manageable.
Bottom Line
- Awiqli is not yet available in Uzbekistan officially
- If/when it arrives, expect pricing closer to 700,000-950,000 so'm/month for 210 units/week (based on US/EU pricing benchmarks)
- India's cheaper launch price (~393,000 so'm/month) may be a reference point if Novo Nordisk uses similar emerging-market pricing for Central Asia
- For now, patients in Uzbekistan would need to import it privately, with unpredictable costs and no regulatory guarantee
This is a shared conversation. Sign in to Orris to start your own chat.